Organogenesis Holdings Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Organogenesis (Nasdaq: ORGO) announced inducement equity awards tied to its newly hired Chief Technology Officer, Michael Catarina, effective October 29, 2025.

The Board granted 82,542 non‑statutory stock options (NSOs) with an exercise price of $4.17 per share and 47,962 restricted stock units (RSUs). Both awards vest in substantially equal annual installments over four years beginning October 20, 2025, subject to continued employment. Although granted outside the 2018 Equity Incentive Plan, the awards are governed by that plan's terms and the related award agreements.

The awards were made as an inducement material to Mr. Catarina’s acceptance of employment pursuant to Nasdaq Listing Rule 5635(c)(4).

CANTON, Mass., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (the “Company”) (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced that effective October 29, 2025, the Company’s Board of Directors granted inducement awards to Michael Catarina, the Company’s newly hired Chief Technology Officer, consisting of non-statutory stock options to purchase 82,542 shares of the Company’s Class A common stock (“NSOs”) and restricted stock units for 47,962 shares of Class A common stock (“RSUs”).

The NSOs have an exercise price of $4.17 per share, the closing price of the Company’s Class A common stock on October 29, 2025, and the NSOs and the RSUs will each vest annually in substantially equal installments over four years from October 20, 2025, subject to Mr. Catarina’s continued employment on each applicable vesting date. While granted outside of the Company’s 2018 Equity Incentive Plan, as amended (the “2018 Plan”), the NSOs and RSUs are subject to the terms and conditions of the 2018 Plan and the respective terms and conditions of the stock option and RSU agreements covering the awards.

The NSO and RSU awards were made as an inducement material to Mr. Catarina’s acceptance of employment with the Company pursuant to Nasdaq Listing Rule 5635(c)(4).

About Organogenesis Holdings Inc.

Organogenesis Holdings Inc. is a leading regenerative medicine company focused on the development, manufacture, and commercialization of solutions for the advanced wound care and surgical and sports medicine markets. Organogenesis offers a comprehensive portfolio of innovative regenerative products to address patient needs across the continuum of care. For more information, visit www.organogenesis.com.

Investor Inquiries:
ICR Healthcare
Mike Piccinino, CFA
OrganoIR@icrinc.com

Press and Media Inquiries:
Organogenesis
communications@organo.com 

FAQ

What equity awards did Organogenesis (ORGO) grant to its new CTO Michael Catarina on October 29, 2025?

The Board granted 82,542 non‑statutory stock options and 47,962 restricted stock units to Michael Catarina.

What is the exercise price and vesting schedule for ORGO's October 2025 NSO grants?

The NSOs have an exercise price of $4.17 per share and vest in substantially equal annual installments over four years from October 20, 2025, subject to continued employment.

Were the ORGO inducement awards granted under the company’s 2018 Equity Incentive Plan?

The awards were granted outside the 2018 Equity Incentive Plan but are subject to the 2018 Plan terms and the related option and RSU agreements.

Why did Organogenesis make these stock awards to Michael Catarina under Nasdaq rules?

The awards were made as an inducement material to Mr. Catarina’s acceptance of employment pursuant to Nasdaq Listing Rule 5635(c)(4).

When do the ORGO NSOs and RSUs begin vesting for the new CTO?

Vesting for both the NSOs and RSUs begins on October 20, 2025 and occurs annually in substantially equal installments over four years, subject to continued employment.